AU1854901A - Novel method - Google Patents

Novel method

Info

Publication number
AU1854901A
AU1854901A AU18549/01A AU1854901A AU1854901A AU 1854901 A AU1854901 A AU 1854901A AU 18549/01 A AU18549/01 A AU 18549/01A AU 1854901 A AU1854901 A AU 1854901A AU 1854901 A AU1854901 A AU 1854901A
Authority
AU
Australia
Prior art keywords
novel method
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18549/01A
Inventor
Craig Antony Joseph Laferriere
Jan Poolman
Moncef Mohamed Slaoui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of AU1854901A publication Critical patent/AU1854901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU18549/01A 1999-10-28 2000-10-27 Novel method Abandoned AU1854901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9925559 1999-10-28
GBGB9925559.8A GB9925559D0 (en) 1999-10-28 1999-10-28 Novel method
PCT/EP2000/010733 WO2001030390A2 (en) 1999-10-28 2000-10-27 Method

Publications (1)

Publication Number Publication Date
AU1854901A true AU1854901A (en) 2001-05-08

Family

ID=10863574

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18549/01A Abandoned AU1854901A (en) 1999-10-28 2000-10-27 Novel method

Country Status (6)

Country Link
EP (1) EP1223987A2 (en)
JP (1) JP2003512440A (en)
AU (1) AU1854901A (en)
CA (1) CA2388995A1 (en)
GB (1) GB9925559D0 (en)
WO (1) WO2001030390A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375704T5 (en) * 2000-06-29 2016-03-03 Smithkline Beecham Biologicals S.A. Composition of multivalent vaccine
KR100947751B1 (en) 2001-01-23 2010-03-18 아벤티스 파스퇴르 Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ATE552844T1 (en) 2003-01-30 2012-04-15 Novartis Ag INJECTABLE VACCINE AGAINST MULTIPLE MENINGOCOCC SEROGROUPES
BR122017002991B1 (en) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. AQUEOUS IMMUNOGENIC COMPOSITIONS FOR MULTIPLE MENINGOCOCCAL SEROGROUPS
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
BRPI0417689A8 (en) 2003-12-17 2017-04-25 Elan Pharm Inc METHOD FOR CONJUGATING A PEPTIDE IMMOGEN, COMPOSITION, CONJUGATE, IMMUNOGENIC COMPOSITION, METHOD FOR INDUCING AN IMMUNE RESPONSE IN A MAMMAL INDIVIDUAL, AND, USE OF THE CONJUGATE
SI1896065T2 (en) 2005-06-27 2014-12-31 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ES2383209T3 (en) 2006-03-22 2012-06-19 Novartis Ag Regimens for immunization with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
CA2662051A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
UY31064A1 (en) 2007-05-02 2009-01-05 Glaxosmithkline Biolog Sa VACCINE
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CN101951949B (en) 2007-10-19 2013-10-02 诺华股份有限公司 Meningococcal vaccine formulations
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
JP5668049B2 (en) 2009-03-24 2015-02-12 ノバルティス アーゲー Combination of meningococcal factor H binding protein and pneumococcal saccharide conjugate
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
MX2012004850A (en) 2009-10-27 2012-05-22 Novartis Ag Modified meningococcal fhbp polypeptides.
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
CN102507924B (en) * 2011-11-17 2014-06-18 成都欧林生物科技股份有限公司 Method for detecting concentration of polysaccharide in zymotic fluid
JP5957541B2 (en) 2012-02-02 2016-07-27 ノバルティス アーゲー Promoter for increased protein expression in Neisseria meningitidis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604108A (en) * 1992-09-14 1997-02-18 Connaught Laboratories, Inc. Test for determining the dose response of a conjugated vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JP2002540074A (en) * 1999-03-19 2002-11-26 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine

Also Published As

Publication number Publication date
CA2388995A1 (en) 2001-05-03
EP1223987A2 (en) 2002-07-24
WO2001030390A3 (en) 2002-04-04
GB9925559D0 (en) 1999-12-29
WO2001030390A2 (en) 2001-05-03
JP2003512440A (en) 2003-04-02

Similar Documents

Publication Publication Date Title
AU1854901A (en) Novel method
AU1173201A (en) Skin-gripper
AU3092999A (en) Digital-timeshare-exchange
AU1538901A (en) Polymersation process
AU4115400A (en) Short-circuiter
AU2804600A (en) Arylaminoalkylamides
AU2023701A (en) Sketcher
AU6098300A (en) Follistatin-3
AU4916900A (en) Benzofuranylsulfonates
AU7273000A (en) Novel processes
AU2359301A (en) Novel ss-defensins
AU4561600A (en) Benzofuranylaminoalcohols
AU1038501A (en) Novel processes
AU1901801A (en) Glucofuranoses
AU1915601A (en) Periotome
AU2582200A (en) Windturbine
AU4435300A (en) Hula-hoop
AU5552200A (en) Method
AU6169100A (en) Novel process
AU1165801A (en) Novel process
AU5550700A (en) Novel process
AU2290401A (en) Novel processes
AU4585100A (en) Method
AU2197301A (en) Microlamp
AU5416100A (en) Retinoscopes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase